In another cohort, Bosse et al [9] retrospectively studied L1CAM in the PORTEC 1 and 2 randomised trials and showed a higher distant relapse as well as worse OS for L1CAM-positive tumours. This evidence concerns the gene L1CAM and neoplasm.